FirsthandHealth
medRxiv PreprintsInternational19 November 2026

lncSigAML: An AI-derived Long Non-coding RNA Prognostic Signature with Multi-Cohort Validation across 2,681 Patients with Acute Myeloid Leukemia

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Acute myeloid leukemia (AML) is clinically and genetically heterogeneous. Current risk stratification systems based on cytogenetic and genetic abnormalities do not fully capture prognostic heterogeneity, particularly among intermediate-risk patients. Long non-coding RNAs (lncRNAs) have emerged as key regulators of AML biology, contributing to leukemogenesis, impaired differentiation, apoptosis resistance, and treatment response. In this study, we developed we developed a bone marrow-derived lncRNA prognostic signature, termed lncSigAML, using in pediatric samples from TARGET-AML (n = 1,594) an
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.